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Crystal structure of human mitochondrial NAD(P)+-dependent
malic enzyme: a new class of oxidative decarboxylases
Yingwu Xu1, Girija Bhargava1, Hao Wu2, Gerhard Loeber3 and Liang Tong1*
Background: Malic enzymes catalyze the oxidative decarboxylation of malate to
pyruvate and CO2 with the concomitant reduction of NAD(P)+ to NAD(P)H.
They are widely distributed in nature and have important biological functions.
Human mitochondrial NAD(P)+-dependent malic enzyme (mNAD-ME) may have
a crucial role in the metabolism of glutamine for energy production in rapidly
dividing cells and tumors. Moreover, this isoform is unique among malic enzymes
in that it is a cooperative enzyme, and its activity is controlled allosterically.
Results: The crystal structure of human mNAD-ME has been determined at
2.5 Å resolution by the selenomethionyl multiwavelength anomalous diffraction
method and refined to 2.1 Å resolution. The structure of the monomer can be
divided into four domains; the active site of the enzyme is located in a deep
cleft at the interface between three of the domains. Three acidic residues
(Glu255, Asp256 and Asp279) were identified as ligands for the divalent cation
that is required for catalysis by malic enzymes. 
Conclusions: The structure reveals that malic enzymes belong to a new class
of oxidative decarboxylases. The tetramer of the enzyme appears to be a dimer
of dimers. The active site of each monomer is located far from the tetramer
interface. The structure also shows the binding of a second NAD+ molecule in a
pocket 35 Å away from the active site. The natural ligand for this second
binding site may be ATP, an allosteric inhibitor of the enzyme.
Introduction
Malic enzyme (ME; EC 1.1.1.40) catalyzes the oxidative
decarboxylation of L-malate to pyruvate with the concomi-
tant reduction of the cofactor NAD+ or NADP+ [1–5]. In
addition to NAD(P)+, the enzyme also requires divalent
cations (Mg2+ or Mn2+) as cofactors.
Mg2+
NAD(P)+ + L-malate ↔ NAD(P)H + pyruvate + CO2
MEs can be divided into three groups on the basis of their
requirement for the dinucleotide cofactor: NAD+- or
NADP+-dependent enzymes that can only use NAD+ or
NADP+ as the cofactor, respectively, and NAD(P)+-
dependent ‘dual-specificity’ enzymes that can use both
NAD+ and NADP+ as cofactor.
ME activity was first isolated from pigeon liver [6]. Since
then, MEs have been found in most living organisms,
including bacteria, yeast, fungi, plants, humans and other
animals. The cDNA sequences of more than 40 different
MEs have been determined. In mammals, three isoforms of
ME have been identified [7]: cytosolic NADP+-dependent
ME (cNADP-ME), mitochondrial NADP+-dependent ME
(mNADP-ME), and mitochondrial NAD(P)+-dependent
ME (mNAD-ME). mNAD-ME can use both NAD+ and
NADP+ as the cofactor (dual-specificity), but prefers NAD+
under physiological conditions.
As suggested by their wide distributions in nature, MEs
have important biological functions. The biochemical
reaction catalyzed by ME produces pyruvate, CO2 and
NAD(P)H, and different biological processes can be sup-
ported by these products. For example, because of the
CO2 production, ME has a crucial role in the photosyn-
thetic reactions in tropical C4 plants [8]. Studies of this
ME may also help delineate the evolutionary process for
the photosynthetic pathway in C4 plants [9,10]. In fungi
and other organisms, an ME, via the NADPH product, is
believed to have lipogenic functions [11]. Similarly, the
cNADP-ME isoform in mammals is involved in the gener-
ation of NADPH and the biosynthesis of fatty acids and
steroids in liver and adipose tissues [8]. cNADP-ME is
under dietary control and can be induced by a carbohy-
drate-rich diet or thyroid hormones. A thyroid response
element is present in the promoter region of the cNADP-
ME gene [12]. cNADP-ME may also have a role in micro-
somal drug detoxification [13].
In comparison, the mNAD-ME isoform, via the NADH
and pyruvate products, is believed to have an important
role in energy production in rapidly proliferating tissues
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(e.g. spleen, thymus, mucosal cells of small intestine), and
particularly in tumors [3,14]. mNAD-ME may be crucial
for the metabolism of glutamine, which is the most abun-
dant single amino acid in plasma, tissues and cell culture
media [15]. Glutamine is the major energy source of many
tumor cells [13,14], many of which do not have a strict
requirement for glucose for energy production [16]. A pos-
sible pathway for the metabolism of glutamine to pyruvate
has been proposed [15] (GL, unpublished results).
Glutamine → glutamate → α-ketoglutarate → succinate →
fumarate → malate → pyruvate
This pathway has been termed ‘glutaminolysis’ [15], in
analogy to the glycolysis pathway that converts glucose to
pyruvate. The part of the pathway that converts α-ketog-
lutarate to malate is actually in the citric acid cycle (Krebs
cycle) [8]. The next reaction in the citric acid cycle is the
oxidation of malate to produce oxaloacetate, catalyzed by
malate dehydrogenase (MDH). In the glutaminolysis
pathway, however, malate is converted to pyruvate by
oxidative decarboxylation, which is catalyzed by ME.
MEs are generally homotetramers, with monomers contain-
ing ~550 amino acid residues and having molecular weights
of ~60 kDa. These enzymes are therefore much larger than
the dehydrogenases (including MDH). Heterodimeric
MEs have been identified from some plants [17] and the
thermophilic bacterium Bacillus stearothermophilus [18]. As
expected from their important biological functions, the
amino acid sequences of MEs from various organisms show
significant conservation. For example, human, rat and
mouse cNADP-ME share 90% sequence identity [7].
Human mNAD-ME shares 55% sequence identity with
human mNADP-ME or cNADP-ME. Another remarkable
example of the high degree of conservation is that the
human mNADP-ME and the maize chloroplast NADP-
ME share 47% amino acid sequence identity [7].
The amino acid sequences of ME contain two copies of
the dinucleotide-binding signature motif GXGXXG/A
(single-letter amino acid code) [19], corresponding to 168-
GLGDLG-173 and 311-GAGEAA-316 in mNAD-ME.
Apart from these two motifs, ME does not show recogniz-
able sequence homology to other proteins, for example
the dehydrogenases (including MDH) and the decarboxy-
lases. The crystal structures of three oxidative decarboxy-
lases are known: 6-phosphogluconate dehydrogenase
(6PGDH) [20], isocitrate dehydrogenase (ICDH) [21] and
isopropylmalate dehydrogenase (IpMDH) [22]. ICDH
and IpMDH have detectable amino acid sequence homol-
ogy (25% identity) and have similar backbone folds. The
sequence and structure of 6PGDH share no homology
with those of ICDH or IpMDH. The amino acid
sequences of ME do not show any homology to these
three proteins or any other oxidative decarboxylases.
Therefore, MEs may have a distinct backbone structure
and form a new class of oxidative decarboxylases.
We have chosen to study human mNAD-ME as a model
system to obtain greater understanding of the biochem-
istry and biology of this important class of enzymes. In
addition, the dual-specificity of mNAD-ME offers the
unique opportunity of studying the same enzyme bound
to NAD+ and NADP+. Such studies should increase our
understanding of the structural basis for cofactor selectiv-
ity [19,23–25]. Furthermore, mNAD-ME is distinct from
the other two mammalian ME isoforms in that it is a coop-
erative enzyme with respect to the substrate malate, and
because its catalytic activity is allosterically controlled by
fumarate (and to a lesser extent succinate) as an activator
and by ATP as an inhibitor [26]. Fumarate and ATP have
no effects on the catalytic activity of cNADP-ME and
mNADP-ME. As a first step in these studies, we report
here the crystal structure of human mNAD-ME in
complex with NAD+ at 2.1 Å resolution. The crystalliza-
tion of ME from rat liver [27] and the nematode Ascaris
suum [28] have been published, however, no structural
information has so far been reported on any ME.
Results
The structure of the monomer
The structure of human mNAD-ME was determined at
2.5 Å resolution by the selenomethionyl multiwavelength
anomalous diffraction (MAD) method [29] and sub-
sequently refined to 2.1 Å resolution. The positions of 28
selenium sites were successfully located based on the
MAD analysis, which represents one of the largest number
of sites that have been solved with the FA approach as
implemented in the MADSYS program [29]. The current
atomic model contains residues 23–573 for each of the two
monomers in the asymmetric unit. Four residues at the N
terminus together with 11 at the C terminus of the protein
are disordered. Two NAD+ molecules are associated with
each monomer of mNAD-ME. The crystallization solu-
tion also contained Mg2+ and tartronate, a substrate analog
inhibitor; however, it appears that they are not bound to
the enzyme in the crystal.
The two monomers of mNAD-ME in the asymmetric unit
have very similar conformations: the root mean square
(rms) distance between the 551 equivalent Cα positions is
0.34 Å. Three regions show distances of ~1 Å (residues
298–304, 505–509 and 568–573); the latter region com-
prises residues at the tetramer interface. The two
monomers are related by a twofold rotation (179.4°) along
a direction perpendicular (90.6°) to the crystal twofold (c)
axis. A tetramer of the enzyme is generated by this crystal-
lographic twofold axis.
The structure of the mNAD-ME monomer can be divided
roughly into four domains (A, B, C and D) (Figure 1).
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Domain A consists of residues 23–130 and is mostly helical
(αA1–αA6). Helix αA6 has a bulge in the middle, resulting
in a sharp turn in the direction of the helix. This might be
due to the presence of the strictly conserved Pro109 and
Pro114 residues. Domain B comprises two segments of 
the polypeptide chain, residues 131–277 and 467–538
(Figure 2a). The distance between the Cα atoms of residues
278 and 467 is 7.6 Å, suggesting that residues 278–466
(domain C) can be considered as an inserted cassette for the
second domain. Domain C (residues 278–466) comprises a
parallel β sheet (βC1–βC7) surrounded by helices on both
sides (αC0–αC5). The topology of this domain is similar to
the canonical Rossmann fold [30], although there are also
significant variations (Figure 2b). The last domain (residues
539–573), contains one helix followed by a long extended
structure that protrudes away from the monomer. The struc-
ture of 6PGDH also contains a Rossmann fold domain,
although it is located at the N terminus [20]. Overall, the
backbone fold of mNAD-ME shows no similarity to that of
ICDH, IpMDH or 6PGDH. MEs therefore represent a new
class of oxidative decarboxylases.
A new fold in domain B 
Domain B contains a parallel five-stranded β sheet
(βB1–βB5) surrounded by helices on both sides (αB1
through αB8; Figure 2a). The parallel β sheet has the con-
nectivity 1,3,2,4,5 (Figure 2a). Searches for structural
homologs, with the program DALI [31] and the SCOP
data base [32], have so far failed to reveal another protein
structure with a similar β sheet. Therefore, this domain of
ME may represent a new polypeptide backbone fold for a
five-stranded parallel β sheet. Without the first strand, the
remaining four-stranded parallel β sheet, with the connec-
tivity 2,1,3,4, has been found in many protein structures. 
This domain is made up of two segments of the polypep-
tide chain. The entire parallel β-sheet structure, together
with five helices, is enclosed in the first segment. The
second segment contains one helix, αB5, that packs
against one face of the β sheet and shields it from the
solvent. Helices αB5, αB6 and αB8 form an antiparallel
bundle, with a hydrophobic core (Figure 2a).
There is a short β-hairpin structure (βB2′–βB3′) between
strand βB2 and helix αB2. The residues in this region,
160-TDGERILGLGDLG-173, correspond to one of the
highly conserved sequence motifs in MEs (Figure 3). This
region also contains the first GXGXXG motif in MEs,
168-GLGDLG-173, with the first glycine (Gly168) at the
tip of the β hairpin. Contrary to expectations from the
sequence analysis, the residues in this motif are not
involved in NAD+ binding. This β-hairpin structure is
near the nicotinamide ring of the NAD+ molecule associ-
ated with domain C, however, and may therefore be
involved in substrate binding by the enzyme.
A Rossmann fold in domain C
The second dinucleotide-binding signature motif,
311-GAGEAA-316, is located between βC1 and αC1 in
domain C (Figure 2b), similar to the location of this motif
in other Rossmann fold structures [19,30]. Strongest simi-
larity was found between the structure of this domain and
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Figure 1
Stereoview schematic drawing of the mNAD-
ME monomer [63]. The β strands are shown
in cyan, α helices in yellow, and the
connecting loops are in purple. The four
domains of the structure are labeled. The two
NAD+ molecules bound to the enzyme are
shown as stick models colored according to
atom type: carbon gray, oxygen red, nitrogen
blue, and phosphorus yellow. The helices in
domain A are labeled. The putative active site
of the monomer is indicated by the red star.
the Rossmann fold domain of D-3-phosphoglycerate dehy-
drogenase (Protein Data Bank [PDB] entry code 1PSD)
[33], and the related NAD-dependent formate dehydroge-
nase (2NAD) [34], D-glycerate dehydrogenase (1GDH)
[35] and D-2-hydroxyisocaproate dehydrogenase (1DXY)
[36]. For example, a structural alignment between domain
C of mNAD-ME and 1PSD brought 119 Cα atoms into
equivalent positions (within a distance of 3.5 Å), and the
rms deviation between these Cα positions was 1.9 Å. The
maximum amino acid sequence identity between mNAD-
ME and other Rossmann fold domains based on the struc-
tural alignment was 15%, indicating a high degree of
structural conservation in the absence of sequence conser-
vation for the Rossmann fold.
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Figure 2
Domains of the mNAD-ME structure.
(a) Stereoview schematic drawing of the
structure of domain B of human mNAD-ME.
The β strands and α helices are labeled; the
color-code is the same as in Figure 1.
Residues at the end of the first polypeptide
segment and the beginning of the second
segment are labeled in green. (b) Stereoview
schematic drawing of the structure of domain
C of human mNAD-ME. The β strands are
numbered according to the consensus with
other Rossmann fold structures. Strand β3 is
absent in the structure of mNAD-ME. The
bound NAD+ molecule is shown as a stick
model and labeled. (c) Stereoview
comparison of the structures of mNAD-ME
and D-3-phosphoglycerate dehydrogenase
(PDB accession code 1PSD) [33] near the
NAD+ molecule. The Cα traces, together with
some sidechains involved in NAD+ binding,
are shown for mNAD-ME (carbon atoms in
cyan) and 1PSD (in gray). The NAD+
molecule in the mNAD-ME structure is shown
with carbon atoms in purple and the NAD+
molecule in 1PSD is in green. The locations of
some of the secondary structure elements of
the Rossmann fold are labeled in red. The
Glu269–His292 pair of residues is conserved
in many dehydrogenases and is involved in
catalysis [64].
Domain C of mNAD-ME starts with a long helix (αC0;
residues 278–298) that packs against the β sheet
(Figure 2b); residue Asp279 near the N terminus of this
helix is involved in binding the divalent cation (see
below). This helix is observed in most other Rossmann
fold structures and should be considered as an integral
component of the Rossmann fold, as it shields part of the
central β sheet from solvent. The residues that form this
helix have, however, been found in different regions of
primary sequence of the various proteins — both N- and
C-terminal to the central β sheet of the Rossmann fold. In
1PSD (and related enzymes 2NAD, 1GDH, 1DXY), gluta-
mate dehydrogenase (1K89) [37] and leucine dehydroge-
nase (1LEH) [38], residues in this helix are located
N-terminal to the β sheet, as also seen here with mNAD-
ME. In other Rossmann fold structures, for example
lactate dehydrogenase (1LDM) [39], this helix is formed
by residues C-terminal to the β sheet, although the posi-
tion and the orientation of the helix is conserved.
There are recognizable differences between the backbone
fold of domain C of mNAD-ME and the canonical Ross-
mann fold. The strand order for the six-stranded parallel
β sheet in a Rossmann fold is normally 3,2,1,4,5,6. In the
structure of mNAD-ME, strand βC3 is absent, however
(Figure 2b). This absence is possibly due to the insertion of
an additional helix between strands βC1 and βC2, residues
334–339 (αC1′), that takes up part of the position of βC3.
Residues 348–350 after strand βC2 form a short β-hairpin
segment (βC2′) that makes three hydrogen bonds with
residues in strand βC2 (Figure 2b). An antiparallel strand at
the β3 position was observed in the structure of glutamate
dehydrogenase [37]. An additional strand (βC7) is hydrogen
bonded to βC6 in a parallel fashion in the structure of
mNAD-ME, as seen in many other structures. In the
current structure, there is a β hairpin between strands βC6
and βC7. However, many of the residues in this β hairpin
have rather weak electron density (especially residues
454–458), and this region corresponds to deletions in the
amino acid sequences of many other MEs (Figure 3).
An NAD+ molecule is associated with domain C, at a
position similar to that of NAD+ in other Rossmann fold
domains. The ADP portion of the cofactor in the current
structure is in excellent agreement with that in 1PSD,
although the planes of the two nicotinamide rings are
separated by ~2.6 Å (Figure 2c). The hydroxyl groups on
the adenine ribose are recognized by an aspartate
residue in 1PSD and many other Rossmann fold struc-
tures. The presence of an acidic residue at this position
(at the end of strand β2) is believed to confer NAD+
specificity to the enzyme [23], due to the unfavorable
charge–charge interactions with the 2′-phosphate of
NADP+. This residue is topologically equivalent to
residue 345 in mNAD-ME, which is conserved as aspar-
tate in all the ME sequences irrespective of their cofac-
tor specificity. In the mNAD-ME structure, the
sidechain of Asp345 points away from the ribose
(χ1 = 56° as compared to –157° in 1PSD). This conforma-
tion might explain the dual-specificity of mNAD-ME,
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Figure 3
Sequence alignments of human mNAD-ME,
rat cNADP-ME, maize ME and the putative ME
of E. coli. The red vertical bars represent the
locations of introns in the genomic sequence
of rat ME [65]. A dot represents a deletion,
and a dash represents an identity to the
sequence of human mNAD-ME. The
secondary structure elements in mNAD-ME
are indicated (SS). Residues colored in green
are those that are buried (with less than 25%
accessible surface area) in the monomer.
Residues having special functional roles are
indicated: D or T, a residue at the dimer or
tetramer interface; B, a residue at both dimer
and tetramer interfaces; A, a residue at the
active site; N, a residue at the second NAD+-
binding site. Residues colored in red may be
important for catalysis. Residues shown in
italics are not observed in the current
structure; of these, residues 2–19 (containing
the mitochondrial targeting sequence) are not
included in the expression construct [3,41].
      1   5   10   15   20   25   30   35 | 40   45   50   55   60   65   70   75   80 | 85   90   95  100
Human MLSRLRVVSTTCTLACRHLHIKEKGKPLMLNPRTNKGMAFTLQERQMLGLQGLLPPKIETQDIQALRFHRNLKKMTSPLEKYIYIMGIQERNEKLFYRIL
Rat   ..........MDPRPRRRTHQR -YLT RDHL --DL--E --Q -KIH---C- VN-E-V --VIK-FERLND FDR-LLLDLD -SV-
Maize (76)EAAAASEELPVMPWATSVAS-YTL RDHH --L --EE --DGHY-R---AV LS-ELI KK-MNT-RQYQT--QR-A MNL-- TDRKL-
Ecoli DIQKRVSDMEPK-KKQSYPYA -PVL EFLL --S --SME--RNFN-L---EVV --IEE--E-AWIQYQGFKTEIDH --LRND TTLV
SS                           |αA1|           |-αA2|             |----αA3|    |----αA4|   |---αA5-
Role                        TT D  DD       D   T   TT D BDDDDBD     D   DD DD            D      D  
        105  110  115  120  125  130 |     140  145  150  155 |     165  170  175  180  185  190  195  200
Human QDDIESLMPIVYTPTVGLACSQYGHIFRRPKGLFISISDRGHVRSIVDNWPENHVKAVVVTDGERILGLGDLGVYGMGIPVGKLCLYTACAGIRPDRCLP
Rat   MSNVK F-------------Q--SLAKR ------HK-- IA-VLNA-DV I------ ------CN------- -AGV NQ Q---
Maize IN VVEL -F-------E--QK-S -GQ --YVL KKK -LEVLR--HRN IQVIC-----------CQ------- -ALGV DS V---
Ecoli NNHLDEM--VI------A--ERFSE-YSR V -Y QNHN MDDL Q-VNHN IVI------ ------QIGI- -SG-- SA YT--
SS  |  |-------αA6|          |βB1|      |-αB1|       |-βB2|  |β|  |β|     |-----αB2|       |--
Role             AAA AA  AA  DD DDDD  DD   TBT T  TD  D D  N N        AAAAA      A  AA  A        NNN  N
        205     | 215  220  225  230  235  240     | 250  255  260  265  270  275     | 285  290  295  300
Human VCIDVGTDNIALLKDPFYMGLYQKRDRTQQYDDLIDEFMKAITDRYGRNTLIQFEDFGNHNAFRFLRKYREKYCTFNDDIQGTAAVALAGLLAAQKVISK
Rat   ITL----EEE ----L -I--RHRV GPE --AFL----EAS SK-M- C------A NL----L-N---N--------SV------ LRITKN
Maize ITI----NEF --N-E--I--R--A TGEE--E--E---SVK QF-EK V------A -----DL-E-S KSHLV----SV------- LMVGG
Ecoli VL---- NQQ --N-L --W RNPI TDDEY EFV--I QVK QW P.DVL-- --A QKM PL-NR--NEIS--- -TVGTI-- SRAAGG
SS  βB3|     |-α|               |------αB3|    |-βB4|   |---αB4|   |βB5|--------αC0|
Role                 DD D DD                                AA                      A
        305  310    |  320  325  330  335  340  345  350  |    360  365  370  375  380  385     | 395  400
Human PISEHKILFLGAGEAALGIANLIVMSMVENGLSEQEAQKKIWMFDKYGLLVKGRKAKIDSYQEPFTHSAPESIPDTFEDAVNILKPSTIIGVAGAGRLFT
Rat   KLD QTVQ-- --------H----A-EKE--KEK R QLV- SK-------.SLTEE KV FA-EHEM..KN LA I-QK--TAL--- AI -GA--
Maize TLA-QTY--------GT---EA LEISQTNAPIE-CR-VLV- SKI- DS-GSLQPF KK-WA-EHEPL..K-LY---QSI-TVLT SV -T --
Ecoli QL--K-V---- -S-GC---EMI SQTQRE--EA R QVFV- RFLT DKMPnLVQK RN LSDWDTDDVLS LL-V-RNV-DIL--- SQ TG---
SS      |-βC1|   |------αC1|    |--α|  |βC2|  |β|         |-αC2|           |--αC3|    |-βC4|
        405  410  415  420  425  430  435   |   445  450  455  460  465  470  475  480  485  490  495 |   
Human PDVIRAMASINERPVIFALSNPTAQAECTAEEAYTLTEGRCLFASGSPFGPVKLTDGRVFTPGQGNNVYIFPGVALAVILCNTRHISDSVFLEAAKALTS
Rat   EQILKD--AF---I----- SK S- -C- KV-K--AI-------D--T-PT LF------SVGVA- GL---N--TT- EVISQ
Maize KEI-ES F ---IS-- SH S-----Q---WSQ--SI-------A--EY.EKT V-- -S--ALGGLVIS GAVRVHEDMLAS -A D
Ecoli EEI--EH KHCP-IVMP-- SR VAP QDIIAW---NAVT-- --N--V.WKDKIYPIA-C--AFIGGAS GASR-TE MLMSS ETA Q
SS  |--αC4|   |-βC5|           |--αC5|    |βC6|    |-β|   |β|  |β|  |-----αB5|       |-----αB6----
Role                      AAA                      AAA               A AAA  A    N  NN N
        505  510   515  520  525    |  535  540  545  550  555  560  565  570  575  580 584
Human QLTDEELAQGR.LYPPLANIQEVSINIAIKVTEYLYANKMAFRYPEPEDKAKYVKERTWRSEYDSLLPDVYEWPESASSPPVITE.
Rat   V SK H-EE--.-----NT-RDL KV -IVQDA-KE---TV----QN-EEF-SSQMYSTN-QICSEVQKIQT KVNQ
Maize A QD NFEKS .IFF TS-RKIA HA AA GKA-ELGL-TLP -S-LV-A ENCMYTPV-RNYR...................
Ecoli YSPLVLNGEM .VLE- KD-K R AF AG KMAQQQGV-VKTSA.A LQQAIDDNF-QA--RDYRRTSI...............
SS  |  |-αB7|         |-------αB8|            |--αD|
Role                                           TNTT       N   N N        TTTT TT
Structure
and the NADP+ dependence of other MEs with a con-
served aspartate at this position.
The adenine ring of NAD+ is on the surface of the protein
and positioned between the sidechain of the residue
immediately following the conserved aspartate in the
primary sequence (Lys346 in mNAD-ME) and that of the
last residue in strand β4 (Ala393 in mNAD-ME;
Figure 2c). No specific recognition of the N1 and N6
atoms of adenine was observed. The nicotinamide ring is
located deeper in the structure, at the interface between
domains C, B and A. The amido nitrogen of the nicotin-
amide group is recognized by two hydrogen bonds with
the protein, involving the mainchain carbonyl of residue
465 and the sidechain of Asn467 (from the linker between
domains B and C). Gly446 is located close to this amide
group and is strictly conserved among MEs. Mutation of
the equivalent Gly444 residue of Saccharomyces pombe ME
to an aspartate inactivated the enzyme [40].
The tetramer
The tetramer of mNAD-ME obeys 222 point group symme-
try (Figure 4) [41], and each monomer in the tetramer has
essentially the same environment. The four monomers are
arranged in the planar rather than tetrahedral fashion; this
arrangement was also observed in electron microscopy
studies of pigeon liver ME [42]. The dimensions of the
tetramer are ~110 Å × 110 Å × 55 Å, consistent with electron
microscopy [42] and solution light-scattering studies [41].
The formation of the tetramer gives rise to the burial of
~2900 Å2 surface area for each monomer. Of this, 1800 Å2
is rendered inaccessible to solvent upon the formation of
the dimer and 1100 Å2 is buried at the tetramer interface.
The dimer interface is contiguous, with intimate associa-
tion of the two monomers (Figure 4). In comparison, the
association between the two dimers appears to be rather
loose, and there are solvent channels at the interface.
The tetramer therefore appears to be a dimer of dimers.
This is consistent with biochemical studies, which
showed that ME exists in a monomer↔dimer↔tetramer
equilibrium in solution [43]. Earlier kinetic and sub-
strate-binding studies on the tetramer of pigeon liver ME
showed that only two of the four active sites of the
tetramer were catalytically competent [1]. An asymmetric
model for the pigeon liver ME tetramer was proposed
[44], requiring head-to-tail packing of the two dimers to
cover up two of the active sites in the tetramer. A
tetramer with such head-to-tail packing will not obey 222
point group symmetry, however, and is therefore incon-
sistent with the tetramer structure observed here for
human mNAD-ME.
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Figure 4
The tetramer of mNAD-ME. (a) Schematic
drawing of the tetramer of human mNAD-ME,
looking down the (crystallographic) twofold
axis. The monomers are colored in green,
cyan, yellow and purple. The bound NAD+
molecules are shown in stick representation.
The active site of one monomer is indicated
by a red star. The dimer and tetramer
interfaces are labeled. (b) The structure of the
tetramer, after 90° rotation around the
horizontal axis, showing the intimate
association at the dimer interface. (c) The
tetramer after a 90° rotation around the
vertical axis, looking down the tetramer
interface. Ignoring the nicotinamide rings of
the second NAD+ molecule, which are
disordered in the structure, there are solvent
channels between the two dimers.
(d) Molecular surface representation of the
tetramer [66], in the same view and color
scheme as (a).
The dimer interface involves residues from domains A and
B of the monomer (Figure 3). Helices αA3 and αA4 run par-
allel to the twofold axis of the dimer and are located at the
dimer interface. There is a mainchain hydrogen bond from
the carbonyl of residue 52 (in the loop between helices αA2
and αA3) to the amide of residue 134 (in strand βB1 of the
other monomer). Four charged sidechains from one
monomer (Glu90, Arg91, Arg128 and Arg129) are located
close to their symmetry-mates in the other monomer,
forming a highly polar interface at the dimer twofold axis.
Most of the 1100 Å2 surface area of each monomer that
becomes buried on tetramer formation is mediated by the
long, extended segment at the C terminus of the protein
(residues 566–573). This segment reaches into the other
dimer of the tetramer and interacts with residues in both
monomers of that dimer. This interface provides ~950 Å2 of
the buried surface area and therefore appears to be the
driving force for tetramerization. The four C-terminal tails
are arranged as two pairs, both of which are located near the
(crystallographic) twofold axis of the tetramer (Figure 4). A
hydrophobic core is formed by residues in each pair
(Leu566, Pro567, Val569 and their symmetry mates),
together with residues from helix αA2 (Gln43, Met47 and
Leu48). The sidechains of Tyr570 and Trp572 are each
located in a hydrophobic pocket at the interface of the other
dimer, involving residues from domain A (αA2 and the
αA2–αA3 connection) of one monomer and residues from
domain B (the βB1–αB1 loop and αB1) of the other
monomer. A second interface is located at the other (non-
crystallographic) twofold axis of the tetramer, where residues
541-FRYP-544 are related to their symmetry mates. This
interface contributes ~150 Å2 to the total buried surface area.
Finally, residues 23–24 are located near the (crystallo-
graphic) twofold axis of the tetramer. These residues have
rather weak electron density, however, and their actual con-
tribution to the tetramer interface is difficult to ascertain.
Residues that form the dimer interface of mNAD-ME
show good conservation among the various MEs (Figure 3).
The dimer interface observed here for mNAD-ME may be
maintained in most MEs. The C-terminal segment, which
appears to be the driving force for formation of the
observed tetramer, is conserved among animal MEs, but
shows significant variability in MEs from plants, yeast and
bacteria. For example, the maize ME sequence stops at
residue 566 [45], and the tetramerization of this protein
may occur through a different structural mechanism. It
might also be possible that the tetramer observed here is
not the most stable form of this oligomer for mNAD-ME,
owing to the binding of the second NAD+ molecule. 
The sidechain of residue Phe40, which is strictly conserved
among all the MEs, is located in the center of the hydropho-
bic core between helices αA1 and αA2. Substitution of its
equivalent residue in pigeon liver ME with smaller residues
(alanine or glycine) resulted in mutants that are monomeric
in solution, whereas substitution with tyrosine had little
effect [46]. These experimental observations are in agree-
ment with the current structure. Removal of the phenyl-
alanine sidechain may destroy the hydrophobic core, thus
destabilizing the conformations of the two helices and the
loops connected to them. These residues are crucial for the
formation of the dimer and tetramer interfaces, even though
Phe40 itself is not at the interface (Figure 3).
A second NAD+-binding site
It was expected that there would be one NAD+-binding
site in each monomer of the enzyme. However, the struc-
ture clearly shows the presence of a second NAD+ mol-
ecule in each monomer. This second molecule is located
near the N-terminal end of the parallel β sheet in domain
B, and residues from domain D are also involved in the
binding (Figure 5). The binding of a nucleotide near the
N-terminal end of a parallel β sheet is rather unusual and
has been observed only rarely. This NAD+ molecule is
separated from the one in the active site by a distance of
~35 Å. The nicotinamide ring and its ribose have very
weak electron density, suggesting that they are mostly dis-
ordered in the structure. In the current model, they are
located in a solvent channel between the two dimers of the
tetramer (Figure 4). The binding of this NAD+ molecule is
therefore mediated by the ADP portion of the molecule,
with the adenine ring buried in the protein. It might also
be possible that the bound molecule is actually ADP, a
hydrolysis product of NAD+. The N6 amino group of the
adenine base makes two hydrogen bonds with the main-
chain carbonyls of residues 192 (with a hydrogen-bonding
distance of 2.5 Å) and 556 (3.3 Å). The N1 ring nitrogen
makes a hydrogen bond to the mainchain amide of residue
194 (2.8 Å). This pattern of interactions appears to provide
a specific recognition for the adenine base, and binding of
other bases at this position is likely to be less favorable.
The first phosphate group (equivalent to the α-phosphate
of ATP) forms electrostatic interactions with the sidechains
of Arg542 and Arg556. The second phosphate group (the
β-phosphate) interacts with the sidechains of His154 and
Arg197. The Arg197 sidechain is also involved in an
amino–aromatic interaction with the adenine base [47].
This second NAD+_binding site is unlikely to be catalytic.
The biological function, if any, of NAD+ binding to this
second site is currently unknown. The identity of the
natural ligand(s) of this binding site is also unknown.
However, the structure does suggest that this second site
could be for binding ATP, which is an allosteric inhibitor
of mNAD-ME. ATP does not have any effects on the cat-
alytic activity of the other two human ME isoforms. In this
regard, none of the three arginine residues (Arg197,
Arg542, Arg556) that are important for this binding site are
present in the other two isoforms, or the other MEs. This
suggests that the second binding site may not exist in
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cNADP-ME and mNADP-ME, giving additional support
for this site being the allosteric inhibitor site. Further bio-
chemical and biophysical studies are needed to fully char-
acterize the biological relevance of this second site.
The active site
The nicotinamide ring of the first NAD+ molecule, associ-
ated with domain C, is located in a deep cleft in the struc-
ture at the interface between domains B and C in each
monomer (Figures 1 and 6). This area is likely to be the
active site of the enzyme. The two domains are positioned
such that the C-terminal ends of their parallel β sheets
point towards this active-site region. In addition, several
residues from helix αA6 in domain A are also located close
to the active site. The four active sites in the tetramer are
separated from each other by a distance of ~60 Å, with the
individual active sites located ~30 Å from the dimer or
tetramer interface (Figure 4). Direct interactions between
the active sites are therefore unlikely. Allosteric interac-
tions among the active sites can give rise to cooperativity,
as is the case with mNAD-ME, or possibly anticooperativ-
ity, which has been proposed for pigeon liver ME [48].
Such interactions may be mediated by helix αA6, which
packs against helices αA3 and αA4 in the dimer interface.
It should be noted, however, that many MEs, such as
human cNADP-ME and mNADP-ME, do not display any
cooperative behavior. 
Despite the presence of Mg2+ and the substrate analog
inhibitor tartronate in the crystallization solution,
neither are bound to the enzyme in the crystal. This
suggests that the conformation of mNAD-ME may be an
‘open’ state. The presence of the second NAD+ mol-
ecule in the putative site for the allosteric inhibitor ATP
is consistent with this interpretation. Further structural
studies are needed to determine whether the binding of
the cation and the substrate induces a ‘closed’ conforma-
tion of the enzyme. 
There is a cluster of three strictly conserved acidic residues
near the nicotinamide ring — Glu255, Asp256 and Asp279.
Residues Glu255 and Asp256 are located near the C-termi-
nal end of strand βB4 in domain B, and residue Asp279 is
located near the beginning of helix αC0 in domain C. It is
possible that these three residues are ligands for the diva-
lent cation that is required for ME catalysis (Figure 6). The
identification of Asp279 as a ligand for the cation is consis-
tent with previous observations based on Fe-ascorbate
affinity cleavage and site-specific mutagenesis studies on
the pigeon liver cNADP-ME [49,50]. Affinity cleavage
with the Cu-ascorbate system identified three additional
residues as possible ligands for the cation [51], correspond-
ing to Asp162, Asp215 and Asp488 in mNAD-ME.
However, none of these three aspartate residues are
located near the Asp279 residue in the structure.
Besides the acidic residues mentioned above, several seg-
ments of the protein structure participate in the formation
of the active site. These segments correspond to highly
conserved regions in the amino acid sequences of MEs
(Figure 3), giving further support for their presence in the
active site. From domain A, helix αA6 contributes residues
112-YTPXVGXXCS-121, where X represents an amino
acid with its sidechain pointing away from the active site.
The strictly conserved Tyr112 residue, is part of the bulge
in this helix, and its sidechain hydroxyl group is located
close to the cluster of the three acidic sidechains
(Figure 6). Tyr112 may also be a ligand for the divalent
cation, or it may have a different role in catalysis. The
sidechain of Cys120 is ~17 Å away from the nicotinamide
ring (Figure 6). Its equivalent in duck liver ME can be
covalently modified by the substrate analog bromopyru-
vate, and the modification eliminated the binding of
malate without affecting the binding of NADP+ cofactor
[52]. The structure shows that the effect of Cys120 modifi-
cation on malate binding is likely to be indirect. From
domain B, residues 165-RILGL-169 (in the βB2′–βB3′
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Figure 5
Stereoview drawing showing the second
NAD+-binding pocket. Only the ADP portion
of the NAD+ molecule is shown, with carbon
atoms in cyan. Residues from the protein are
shown with carbon atoms in gray. The
hydrogen bonds from the N1 and N6 atoms
of the adenine base are shown as dotted
purple lines.
hairpin) and 176-GXXIPXXK-183 (helix αB2) are located
near the active site. The Arg165 sidechain interacts with
the diphosphate group of the NAD+ cofactor, although this
residue shows nonconservative substitutions to glycine
and serine in the yeast and B. subtilis MEs. Residues
161–173 correspond to one of the most conserved regions
in MEs and include the GLGDLG motif. The  strictly
conserved Lys183 sidechain interacts with that of Asp278
(the first residue of αC0) and Glu255. Asp278 is conserved
except for a plant ME, where it is a valine. From domain
C, residues 421-NPT-423 (in the βC5–αC5 connection,
with Pro422 in the cis conformation) and 446-GSP-448 (in
the loop after βC6) may be involved in substrate binding.
Finally, residues 464-QXNNVXXF-471, at the boundary
between domains B and C, contribute three conserved
sidechain amide groups to the active-site region. The
sidechain of Asn467 is also involved in recognition of the
nicotinamide group, as discussed earlier. 
In addition to Cys120, chemical modification studies have
indicated the presence of arginine and tyrosine residues in
the active site of various MEs, although the identity of the
residues were not determined from these studies. Modifi-
cation of one tyrosine sidechain of pigeon liver ME
resulted in loss of enzyme activity [53]. On the basis of the
crystal structure, this might correspond to Tyr112 of
mNAD-ME. Modification of one arginine residue in
pigeon liver ME and maize ME eliminated the binding of
malate without affecting the binding of the NADP+ cofac-
tor [54,55]. This suggested that an arginine residue might
be involved in malate binding. In the current structure,
there is only one arginine residue (Arg165) near the active
site. Its sidechain is close to the phosphates of the cofactor
and may be too far from the substrate. However, the con-
formation of this sidechain might be different in the
‘closed’ state of the enzyme, when the substrate is bound.
Overall, the active-site region in mNAD-ME contains
only two positively charged residues, Lys183 and Arg165,
and the latter is not strictly conserved among MEs. This
suggests that ionic interactions might not be a major com-
ponent for the binding of the dicarboxylic malate sub-
strate. This is in contrast to the binding of isocitrate to
ICDH, where the C1 carboxylate group interacts with
three arginine residues [56].
The nicotinamide ring is in the anti conformation, with
the B face packed against residues in domain C
(Figure 6). This conformation is stabilized by specific
recognition of the amide group on the ring, notably by the
conserved Asn467 sidechain. Therefore, MEs are
expected to have A-type stereospecificty for hydride
transfer to the dinucleotide cofactor.
Discussion
The allosteric control of human mNAD-ME is consistent
with its role in the glutaminolysis pathway. Fumarate and
succinate are products from the previous two steps in this
pathway, and their activation of mNAD-ME can help
ensure that there is sufficient ME activity when the
pathway is on. On the other hand, ATP is a universal cur-
rency of free energy in biological systems [8]. Its inhibi-
tion of mNAD-ME may prevent the generation of excess
energy molecules. A similar allosteric control mechanism
has been observed for pyruvate kinase, which catalyzes
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Figure 6
The active site of mNAD-ME. (a) Stereoview drawing showing the
active-site region of mNAD-ME. Protein residues are shown with carbon
atoms in gray. The nicotinamide ribose of the NAD+ molecule is shown
with carbon atoms in cyan; phosphorus atoms are in yellow. To illustrate
the location of the cation-binding site, a magnesium ion has been
modeled into the structure (shown as a magenta sphere). The GLGDLG
motif corresponds to residues 168–173. (b) The molecular surface of
human mNAD-ME near the active-site region [66]. The surface is
colored on the basis of electrostatic potential: red, negative; blue,
positive; white, neutral. The NAD+ molecule is shown as a stick model
colored according to atom type. The three domains of the enzyme are
labeled, as are the positions of several residues in this active-site region.
the last reaction in glycolysis. The L isoform of this
enzyme is allosterically activated by fructose 1,6-bisphos-
phate, the product from the preceding irreversible step in
the pathway, and is allosterically inhibited by ATP [8].
Such a comparison offers additional support for the gluta-
minolysis pathway, and for the importance of mNAD-ME
in energy metabolism. The activity level of this enzyme in
the Morris hepatoma is correlated with the progression of
the malignancy, indicating that energy production in these
tumor cells may be dependent on mNAD-ME [13,14,57]. 
Human mNAD-ME displays cooperativity with respect to
the substrate malate. On the basis of the concerted model
for allosteric interactions, the enzyme tetramer may exist
in a catalytically competent R state and a T state, which
has significantly lower affinity for the substrate. The
binding of the allosteric inhibitor (ATP) stabilizes the
T state and reduces the enzyme activity. The presence of
a second NAD+ molecule in the structure, which possibly
mimics the binding of ATP, suggests that the current
structure may represent the T state of the enzyme.
However, an anticooperativity has been proposed for the
pigeon liver ME [48], which cannot be explained by the
concerted model. The current structure shows that the
tetramer of mNAD-ME may be a dimer of dimers, and it
would be interesting to establish whether the allosteric
interactions occur only within the dimers. In this regard,
preliminary kinetic experiments showed that the Hill
coefficient of the enzyme with respect to malate, in the
absence of fumarate, is ~1.5 (GB and LT, unpublished
data). An understanding of the structural basis of the coop-
erative behavior will have to await further studies. 
Catalysis by MEs generally proceeds in two steps — the
dehydrogenation of malate to produce oxaloacetate (the
same reaction as that catalyzed by MDH), and decarboxy-
lation to produce pyruvate [5]. A general base is needed for
the first step to extract the proton for dehydrogenation,
and a general acid is needed for the second step to proto-
nate the product of decarboxylation. In the functionally
related enzyme ICDH, which also has a two step catalytic
mechanism, one of the aspartate ligands of the cation was
proposed as the general base and a tyrosine or lysine
residue was proposed as the general acid [56]. The situa-
tion with ME is more complicated, as a water-mediated
interaction between the cation and the substrate is
expected [4,58]. This might increase the distance between
the aspartate/glutamate ligands of the cation and malate,
making them less likely to function as the general base. At
the same time, the bridging water molecule could be a
good candidate for the general base. For the general acid,
the structure of mNAD-ME also contains a tyrosine and a
lysine residue in close proximity in the active site
(Figure 6). Further studies, especially the determination of
a structure of the holoenzyme, are needed to fully charac-
terize the functions of these and other residues in catalysis.
NAD+-dependent enzymes are generally associated with
oxidative metabolic processes, and NADP+-dependent
enzymes are generally associated with reductive biosyn-
thesis. The structural basis for this selectivity/specificity
towards the cofactor by the various enzymes is still not
well understood. Earlier studies suggested two specificity
determinants for enzymes that contain Rossmann folds
[19,23]. The presence of a GXGXXG signature motif indi-
cates NAD+ specificity, whereas a GXGXXA motif indi-
cates NADP+ specificity. Secondly, the presence of an
acidic residue near the end of strand β2 of the Rossmann
fold indicates NAD+ specificity, as this residue recognizes
the hydroxyl groups on the ribose. ME appears to violate
both of these ‘rules’. A GXGXXA motif is present in all
animal MEs, whereas a GXGXXG motif is present in all
plant, yeast and bacterial MEs, irrespective of their cofac-
tor specificity. In addition, an aspartate residue is con-
served in all MEs at the end of β2, corresponding to
Asp345 of human mNAD-ME. The current structure
shows that this sidechain points away from the ribose, pro-
viding a possible mechanism for NADP+ binding even in
the presence of this acidic residue. It is not known why
the Asp345 sidechain points away in this NAD+ complex.
mNAD-ME has comparable affinity for NAD+ and
NADP+, with that for NADP+ being about two to fivefold
weaker than for NAD+ [2]. mNAD-ME is a dual-speci-
ficity enzyme, and our experiments with NADP+ binding
to this enzyme suggest that there may be little conforma-
tional differences between the NAD+ and NADP+ com-
plexes of this enzyme. Comparative studies between this
dual-specificity isoform and the NADP+-specific isoforms
of human ME may lead to a greater understanding of the
structural basis of cofactor specificity.
Biological implications
Malic enzymes are widely distributed in nature and have
important biological functions. Their amino acid
sequences show no recognizable homology to those of
other oxidative decarboxylases or to other proteins in
general. This first structure of a malic enzyme confirms
that it belongs to a new class of oxidative decarboxylases,
with a distinct backbone structure. Malic enzymes have
been studied extensively by biochemical, kinetic and muta-
genesis experiments. The crystal structure of human mito-
chondrial NAD(P)+-dependent malic enzyme reported
here provides an explanation, at the molecular level, to
many of these prior observations.
The active site of the enzyme is located in a deep cleft at
the interface of three domains of the enzyme monomer;
residues forming this active site are highly conserved.
The nicotinamide ring of an NAD+ molecule, associated
with a Rossmann fold domain, is located in this active-
site region. The amino acid sequences of malic enzymes
contain two dinucleotide-binding signature motifs
(GXGXXG/A). The structure shows that only one of
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these is involved in binding an NAD+ molecule. The
other motif is located in the active site and may be
involved in substrate binding. Catalysis by malic
enzymes requires the presence of divalent cations (Mg2+
or Mn2+). On the basis of the crystal structure, three
acidic residues (Glu255, Asp256 and Asp279) were iden-
tified as ligands for the cation. The identification of
Asp279 as a ligand is consistent with earlier biochemical
and mutagenesis studies.
The structure shows that the tetramer of the enzyme
appears to be a dimer of dimers. This observation has
potential implications for the allosteric control of the
enzyme. It might be possible that dimers, rather than
tetramers, are the units that display cooperative behav-
ior. A glimpse into the possible mechanism of allosteric
control of this enzyme is provided by the observation of
NAD+ binding to a second site, the natural ligand of
which may be the allosteric inhibitor ATP.
Materials and methods
Protein expression, purification and crystallization
Details of the expression, purification and crystallization of human
mNAD-ME will be presented elsewhere [41]. Briefly, mNAD-ME was
over-expressed in E. coli and purified by anion exchange, ATP affinity
and gel-filtration chromatography [3]. Crystals of mNAD-ME were
obtained at 4°C by the hanging-drop vapor diffusion method. Many
different crystal forms were observed [41]. Crystals used for the
current structure analysis belong to space group B2, with cell para-
meters of a = 204.4 Å, b = 107.0 Å, c = 59.2 Å and γ = 101.9°. There
is a dimer of mNAD-ME in the asymmetric unit, giving a Vm of
~2.5 Å3/Da. For crystallization, the protein concentration was
8 mg/ml, in a buffer containing 30 mM Tris (pH 7.4), 125 mM KCl,
3 mM NAD+ and 10 mM DTT. The reservoir solution contained
100 mM Hepes (pH 7.0), 8% PEG 8000, 5% MPD, 6 mM MgSO4
and 10 mM tartronate.
Structure determination
The structure was determined by the selenomethionyl MAD method
[29]. The selenomethionyl protein was expressed in E. coli in a defined
media, purified and crystallized using protocols that are essentially the
same as for the wild-type protein. The catalytic activity of the selenome-
thionyl protein was comparable to that of the wild-type enzyme, sug-
gesting that the selenomethionyl residues did not have any major
impact on the structure of the enzyme. The MAD data set, to 2.5 Å res-
olution, was collected at beamline X4A of the National Synchrotron
Light Source (NSLS) at Brookhaven National Laboratory. The crystal
was maintained at cryotemperature and the entire data set was col-
lected with one crystal, measuring 0.5 × 0.2 × 0.08 mm3. Four wave-
lengths were used for the MAD data collection: λ1 (12550 eV,
0.9879 Å wavelength, remote), λ2 (12660 eV, 0.9793 Å, edge), λ3
(12663 eV, 0.9791 Å, peak) and λ4 (12800 eV, 0.9686 Å, remote).
Inverse beam geometry was used to collect the Friedel pairs. The dif-
fraction images were recorded on an R-Axis IV imaging plate detector,
and processed with DENZO and SCALEPACK [59]. The oscillation
range per frame was 2°, and the exposure time per frame was ~4 min.
The crystal was aligned with the twofold c axis along the X-ray beam
and the long a axis along the spindle before the start of data collection.
A total of 90° oscillation (together with 90° for the inverse beam
portion) was collected for each wavelength.
The reflection data sets from the four wavelengths were loaded into
the MADSYS program package [29]. The statistics from the MAD
analysis were excellent (Tables 1 and 2), confirming the quality of the
MAD data set and suggesting that the FA values were likely to be
good estimates for the scattering of the Se atoms. There are
14 methionine residues in each monomer (excluding the initiator
methionine residue), therefore a total of 28 Se sites are expected in
the asymmetric unit. Earlier experience with the structure determina-
tion of other proteins have raised some doubts as to the likelihood of
success with the FA approach with these many Se sites [60].
However, by careful selections of input parameters to the program
SHELXS-86 (G Sheldrick) and examinations of its outputs, we were
able to solve the positions of the Se sites with direct methods. The FA
values in the resolution range of 30–3.5 Å were used in the calcula-
tion, which revealed the positions of all 28 Se sites.
The phase information to 2.5 Å resolution from the MAD analysis was
improved by solvent flattening and twofold noncrystallographic sym-
metry (NCS) averaging with a local program (LT, unpublished). The
electron-density map was of sufficient quality, allowing many residues
of the protein to be located (Figure 7). The knowledge of the 14 Se
sites, and therefore the 14 methionine positions in the molecule, pro-
vided independent confirmation for the trace. Residues 346–465 had
weaker and less resolved electron density, suggesting flexibility for
these residues. It was recognized that these residues may have a
Rossmann fold, and the β strands in the Rossmann fold of lactate
dehydrogenase (PDB entry 1LDM) [39] were manually overlayed into
the electron density. This helped the tracing for this domain of the
structure. The model of the protein was built into the electron density
with the program O [61].
Locating NAD+-binding sites
In order to provide an independent observation for the position of the
NAD+ molecule in the protein, we took advantage of the ‘dual-speci-
ficity’ of mNAD-ME. Crystals of the enzyme were grown in the pres-
ence of NADP+ instead of NAD+. An X-ray diffraction data set to
2.4 Å resolution was collected on such a crystal at the F2 beamline
at Cornell High Energy Synchrotron Source (CHESS). These crystals
are isomorphous to those of the NAD+ crystals, allowing a difference
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Table 1
Data processing statistics for MAD data set at λ4.






Anomalous diffraction ratios* from the MAD analysis.
Wavelength λ1 λ2 λ3 λ4
λ1 4.9 (2.8) 4.2 3.6 4.1
λ2 – 5.5 (2.9) 3.0 5.8
λ3 – – 7.8 (2.8) 4.3
λ4 – – – 6.0 (2.7)
*Anomalous diffraction ratios (for 30–4 Å reflection data) are Bijvoet
difference ratios along the diagonal (with those for centric reflections
shown in parentheses); dispersive difference ratios off-diagonal. The
ratios are given as percentages. For phasing, ∆(∆φ) = 30°
and R(FA) = 32%, where ∆(∆φ) is the average difference between
independent determinations of ∆φ from the MAD analysis [29].
electron-density map to be calculated. The map is expected to
contain peaks corresponding to the phosphate groups of the NADP+
molecules. Surprisingly, two peaks were identified in each monomer
of mNAD-ME in the difference map. One of them is associated with
the Rossmann fold and belongs to the NADP+ molecule bound to it.
The other peak is associated with an unexpected second binding site
for NAD(P)+ in mNAD-ME.
Structure refinement
The structure refinement was carried out with the program X-PLOR
[62], using a native data set to 2.1 Å resolution that was collected on a
CCD detector at the F2 beamline of CHESS. NCS restraints were
used throughout the structure refinement, initially on all the atoms and
finally on only the Cα atoms. Residues Gln335 and Lys339 in both
monomers, and residues Lys352 and Arg354 in the first monomer, are
modeled as alanines due to lack of sidechain electron density. The sta-
tistics on the quality of the native reflection data set and the structure
refinement are summarized in Table 3.
Accession numbers
The atomic coordinates for mNAD-ME have been deposited in the
Protein Data Bank with accession code 1QR6.
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